Asfar Azmi

Asfar Azmi

Dr. Asfar S. Azmi, PhD. is an Assistant Professor in the Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan USA. He has more than a decade of research experience in the area of cancer biology and drug discovery. His translational work broadly focuses on designing, developing and testing novel small molecule drugs in a wide variety of solid tumors and hematological malignancies. His research has a special focus on oncogenic KRAS driven tumors, particularly pancreatic ductal adenocarcinoma. Dr. Azmi utilizes cutting edge computational biology in his drug discovery work that has helped in bringing a number of agent into the clinic such as AT-101 (an advanced Bcl-2 inhibitor currently in 23 different clinical trials) and nuclear export inhibitor (Selinexor). Dr. Azmi has published over 100 peer reviewed articles and numerous editorials as well. He served as executive guest editor for 5 different thematic issues in prestigious journals such as Seminars in Cancer Biology and others. He is the editor of a book on Systems Biology in Cancer Research and Drug Discovery for Springer and another book on Molecular Diagnostics and Treatment of Pancreatic Cancer published through Elsevier Academic Press. He is the editor in Chief of Wolters Kluwer Journal Oncobiology and Targets. In summary, Dr. Azmi has proven track record of comprehensive editorial work. He brings with him vast experience necessary to undertake this important project and complete it in a timely fashion.

Affiliations and Expertise

Assistant Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA